About Us:
Chennai Liver Foundation (CLF) is a voluntary, non-profit organisation which aims to promote awareness about liver health by supporting research and educational activities. It offers help, support and information to the medical fraternity and the general public about diagnosis, prevention and treatment of liver related diseases.
Concerned about the increasing incidence of liver disease, Prof. R.P. Shanmugam founded Chennai Liver Foundation in 1997. Later Dr.Vivekanandan joined hands to make CLF the first organization in the India to focus in providing support for research and education into the causes, diagnoses, prevention and treatment of all liver diseases.
The foundation has come a long way since then and intends to help promote further research, provide education about liver wellness and work to find cures and better treatment for all kinds of liver ailments.
Today, our focus remains virtually unchanged from those early days. CLF is committed to spreading awareness and campaigning for organ donation. By encouraging individuals to participate and be alert about their own health care, CLF believes it can make lasting changes in the lives of people.
Our Objectives:
• To improve public awareness and understanding of liver health and liver disease
• Raise funds for research and reach out to poor underprivileged liver disease patients and their families.
• To encourage volunteer chapters across the country to further our causes
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close